Effect of S-ademethionine on Arginine Content and Its Metabolites in Patients with Chronic Lymphocytic Leukemia During Chemotherapy


І. М. Скрипник
Г. С. Маслова


The objective: to investigate the nature of changes in arginine and its metabolites in the dynamics of S-ademethionine administration on the background of program chemotherapy (CT) in patients with B-cell chronic lymphocytic leukemia (B-CLL).

Materials and methods. 26 patients with B-CLL were examined. Depending on the inclusion of S-ademethionine in therapy, patients were divided into two groups: I (n=12) – patients with B-CLL, who received CT; II (n=14) – patients with B-CLL, who on the background of CT was treated with S-ademethionine 1000 mg/day intravenously for 10 days, then 1000 mg/day orally for 18 days. Assessment was performed twice: before the CT started and after 2 courses of CT. The content of arginine, citrulline, arginase activity, ornithine decarboxylase (ODC) in the blood serum was investigated.

Results. Holding CT for patients with B-CLL with inclusion of concomitant therapy with S-ademethionine can increase the arginine level in 1.2 times (p=0.01), the ODC activity – 28 times (p=0.001) and decrease the arginase activity in 1,4 times (p=0.01), the citrulline content – 7.9 times in the blood serum (р=0.0001).

Conclusion. In patients with B-CLL, the appointment of S-ademethionine on the background of CT can reduce the manifestations of arginine/citrulline cycle disorders caused by oncohematological disease.


How to Cite
Скрипник, І. М., & Маслова, Г. С. (2020). Effect of S-ademethionine on Arginine Content and Its Metabolites in Patients with Chronic Lymphocytic Leukemia During Chemotherapy. Family Medicine, (3), 20–23. https://doi.org/10.30841/2307-5112.3.2020.211188
Topical issues
Author Biographies

І. М. Скрипник, Ukrainian Medical Stomatological Academy

Ihor M. Skrypnyk,

Department of Internal Medicine No 1

Г. С. Маслова, Ukrainian Medical Stomatological Academy

Hanna S. Maslova,

Department of Internal Medicine No 1


Антомонов М.Ю. Математическая обработка и анализ медико-биологических данных. – К.: Мединформ, 2018. – 579 с.

Крячок И.А. Хронический лимфолейкоз: новое в лечении подходы к терапии первой линии и их эволюция // Клиническая онкология. – 2013;3(11):121–9.

Стюарт Дж, Янг Дж. Швачкина Ю.П. редактор. Перевод с англ. Мишина ГП. Твердофазный синтез пептидов. – М.: Мир;1971. – С. 129–130.

Храмов В.А., Листопад Г.Г. Модификация метода определения орнитина по Chinard и ее использование для количественного определения сывороточной аргиназы // Лабораторное дело. – 1973;10:591–2.

Храмов В.А. Простой метод определения активности орнитиндекарбоксилазы в смешанной слюне человека // Клиническая лабораторная диагностика. – 1997;4:14–5.

Al-Koussa H., Mais N.E., Maalouf H., Abi-Habib R., El-Sibai Mirvat. Arginine deprivation: a potential therapeutic for cancer cell metastasis? A review. Cancer Cell Int. 2020;20:150. doi: 10.1186/s12935-020-01232-9

Boyde TR, Rahmatullah M. Optimization of conditions for the colorimetric determination of citrulline, using diacetyl monoxime. Analytical Biochemistry. 1980;107:424–31.

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26(Supplement 5):v78–84. doi:10.1093/annonc/mdv303.

Frau M, Feo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. J Hepatol. 2013;59(4):830–41. doi: 10.1016/j.jhep.2013.04.031.

Hosios AM, Hecht VC, Danai LV, Johnson MO, Rathmell JC, Steinhauser ML, et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell. 2016;36(5):540–49. doi: 10.1016/j.devcel.2016.02.012

Lam SK, U KP, Li YY, Xu S, Cheng PN, Ho JC. Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models. Oncol Rep. 2018;40 (4):1994–2004. doi: 10.3892/or.2018.6598.

Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017; 14(2):113. doi: 10.1038/nrclinonc.2016.60В

McCracken AN, Edinger AL. Nutrient transporters: the Achilles’ heel of anabolism. Trends Endocrinol Metab. 2013;24(4):200–8. doi: 10.1016/j.tem.2013.01.002

Morris SM. Recent advances in arginine metabolism: roles and regulation of the arginase. British Journal of Pharmacology. 2009;157(6):922–30. doi: 10.1111/j.1476-5381.2009.00278.x

Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47. doi: 10.1016/j.cmet.2015.12.006

Saltykova LB, Blinov MN. [Polyamine Levels and Biosynthesis in Leukocytes During Leukemic Transformation]. Eksp Onkol. 1987;9(2):18–21.

Stabellini G, Calastrini C, Gagliano N, Dellavia C, Moscheni C, Vizzotto L, et al. Polyamine levels and ornithine decarboxylase activity in blood and erythrocytes in human disease. Int J Clin Pharmacol Res. 2003;23(1):17–22.

Wahlfors J, Hiltunen H, Heinonen K, Hämäläinen E, Alhonen L, Jänne J. Genomic Hypomethylation in Human Chronic Lymphocytic Leukemia. Blood. 1992;80(8):2074–80.

Wang MF, Liao YF, Hung YC, Lin CL, Hour TC, Lue KH, et al. Hydroxydibenzoylmethane induces apoptosis through repressing ornithine decarboxylase in human promyelocytic leukemia HL-60 cells. Experimental and Molecular Medicine. 2011;43(4):189–96. doi: 10.3858/emm.2011.43.4.023.

Werner A, Pieh D, Echchannaoui H, Rupp J, Rajalingam K, Theobald M, et al. Cationic Amino Acid Transporter-1-Mediated Arginine Uptake is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability. Front Oncol. 2019; Available from: https://doi.org/10.3389/fonc.2019.01268